Oneness Biotech's COVID-19 Treatment Drug SNS 812 Successfully Unblinded in Phase II Trial

On August 8, Microbio and Oneness Biotech jointly announced that SNS812, an antiviral nucleic acid drug developed by Oneness Biotech and Microbio’s subsidiary Microbio Shanghai to treat COVID-19 infections, has successfully met the primary and key secondary endpoints in its Phase II clinical trial. The results indicate that SNS812 is safe and demonstrates significant clinical efficacy against various high immune escape variants, including the globally prevalent JN.1 strain.